Behind the science

Using AI, ML and data to unlock the mysteries of disease

Using AI, ML and data to unlock the mysteries of disease

Our purpose

We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.

Our R&D focus is on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology

Infectious diseases
1 in 6
deaths globally caused by infectious disease
HIV
39m
people living with HIV globally
Respiratory/Immunology
50yrs
of leading research to help people with respiratory and inflammatory conditions
Oncology
~10m
people died from cancer in 2020, making it a leading cause of death worldwide

some description

Life at GSK test

How we help people thrive 

Culture

Growth

Diversity, equity and inclusion

Wellbeing

pinch icon pinch icon

Access

We are making our products affordable and available to more people around the world through responsible pricing, strategic access programmes and partnerships.

Global health and health security

We are committed to change the trajectory of high burden diseases in lower-income countries with a focus on prevention and treatment of infectious diseases.

Environment

We're committed to work towards a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045.

Diversity, equity and inclusion

Our work supports the health of all kinds of people. To meet our diverse patients' needs better, we need diversity in our clinical trials and to support our own people to thrive as part of an inclusive team.

Ethical standards

Our culture guides our people to do the right thing and act on any concerns they have.

Product governance

Ensuring the quality, safety and reliable supply of our products is critical to our purpose of uniting science, talent and technology to get ahead of disease together.

INVESTORS

We announced our first quarter 2024 results on Wednesday 1 May

en-gb

123

  1. 123

GSK Global links

Visit our Global site for additional features

Title

Subtext Subtext Subtext